Back

Activity of ceftaroline against recent (2009) and multidrug-resistant Streptococcus pneumoniae isolates from Europe and the United States

Abstract number: P1877

Farrell D., Moet G., Rhomberg P., Sader H., Jones R.

Objective: To determine the activity of ceftaroline against recent (2009) S. pneumoniae (SPN) and multidrug-resistant (MDR) SPN isolated in Europe (EU) and the United States (USA). Antimicrobial resistance in SPN and MDR-SPN are increasing globally and rapidly in some countries, including the USA. Ceftaroline is a novel, parenteral, broad-spectrum cephalosporin exhibiting bactericidal activity against Gram-positive organisms including SPN and MDR-SPN and is currently in late stage clinical development.

Methods: Susceptibility testing for ceftaroline and commonly used antimicrobials was performed by CLSI broth microdilution methods on a total of 987 isolates from the 2009 Ceftaroline Surveillance Program. MDR-SPN status was determined by resistance to 2 or more classes of antimicrobials.

Results: Ceftaroline MIC50, MIC90, and MIC range (all mg/L) against all isolates and resistance phenotypes are listed in the Table. Ceftaroline was very active against all isolates, with MIC50 and MIC90 of leqslant R: less-than-or-eq, slant0.008 and 0.12 mg/L. MIC50 and MIC90 were slightly higher in drug-resistant SPN and MDR-SPN than in non-MDR-SPN isolates. The highest ceftaroline MIC found was 0.5 mg/L. MIC90 was 1 log2 dilution higher in USA isolates than in EU isolates due to the higher prevalence of MDR-SPN in the USA (21.5% vs. 14.2% in EU). Ceftaroline was very active against isolates resistant to the commonly used antimicrobials penicillin, ceftriaxone, erythromycin, levofloxacin, trimethoprim/sulphamethoxazole (T/S), and tetracycline.

Conclusions: Antimicrobial resistance in SP and MDR-SPN continues to escalate each year, highlighting the need for new antimicrobials. This study demonstrated the potent in vitro activity of ceftaroline against recent (2009) SPN isolates, regardless of MDR status, resistance phenotype, or geographic location (EU or USA). These data suggest that ceftaroline may emerge as an important therapy for infections caused by SPN resistant to b-lactams and other commonly used antimicrobials as well as MDR strains.

 nMIC50MIC90Range
All isolates987leqslant R: less-than-or-eq, slant0.0080.12leqslant R: less-than-or-eq, slant0.008–0.5
All Europe485leqslant R: less-than-or-eq, slant0.0080.12leqslant R: less-than-or-eq, slant0.008–0.5
All USA5020.0150.25leqslant R: less-than-or-eq, slant0.008–0.5
MDRSP1770.120.25leqslant R: less-than-or-eq, slant0.008–0.5
Penicillin geqslant R: gt-or-equal, slanted4 mg/L1090.250.250.06–0.5
Ceftriaxone geqslant R: gt-or-equal, slanted2 mg/L1050.250.250.06–0.5
Erythromycin geqslant R: gt-or-equal, slanted2 mg/L3440.120.25leqslant R: less-than-or-eq, slant0.008–0.5
Levofloxacin geqslant R: gt-or-equal, slanted4 mg/L110.060.25leqslant R: less-than-or-eq, slant0.008–0.25
T/S geqslant R: gt-or-equal, slanted4 mg/L2180.120.25leqslant R: less-than-or-eq, slant0.008–0.5
Tetracycline geqslant R: gt-or-equal, slanted8 mg/L2420.120.25leqslant R: less-than-or-eq, slant0.008–0.5

Session Details

Date: 10/04/2010
Time: 00:00-00:00
Session name: Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases
Subject:
Location: Vienna, Austria, 10 - 13 April 2010
Presentation type:
Back to top